x POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

See other indications for POMALYST:

This website is intended for U.S. Healthcare Professionals.

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

One capsule.
Once daily.

POMALYST® (pomalidomide) can be taken at home or wherever is convenient for your patient.

Recommended dosage for POMALYST is 4 mg once daily orally with or without food on Days 1-21 of each 28-day cycle.

  • POMALYST is given in combination with dex
  • Initiate POMALYST treatment in females of reproductive potential only following a negative pregnancy test. Advise of the importance of monthly pregnancy tests and the need to use 2 different forms of contraception during treatment and for 4 weeks after completion of treatment
  • Advise males to always use latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 4 weeks after discontinuing treatment
  • 3 mg, 2 mg, and 1 mg doses are also available for dose modification



DAYS 1-21

POMALYST® (pomalidomide) 4mg Capsule


(Capsule shown is not actual size)

In the doublet Phase 3 trial, low-dose dex was given on Days 1, 8, 15, and 22 of a 28-day cycle.

  • Dex 40 mg for patients ≤75 years
  • Dex 20 mg for patients >75 years

Repeat until disease progression or unacceptable toxicity. Dose interruptions and modifications may be required.

Important Dosing Information

  • POMALYST may be taken with or without food. Inform patients not to break, chew or open the capsules. Swallow capsules whole with water.
  • Monitor CBCs every week for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification.
  • Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered.
  • Reduce POMALYST dose to 3 mg orally daily in patients with mild to moderate hepatic impairment and to 2 mg in patients with severe hepatic impairment.
  • Avoid concomitant use of POMALYST with strong inhibitors of CYP1A2. If concomitant use of a strong CYP1A2 inhibitor is unavoidable, reduce POMALYST dose to 2 mg.
  • Reduce POMALYST dose to 3 mg orally daily in patients with severe renal impairment requiring dialysis. Take dose of POMALYST following hemodialysis on hemodialysis days.

Permanently discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reaction.

For other Grade 3 or 4 toxicities:

  • Hold treatment and restart treatment at 1 mg less than the previous dose when the toxicity has resolved to <Grade 2 at the physician’s discretion
POMALYST® (pomalidomide) Capsule Icon

A detailed dosing guide is available.


Dosing for
renal impairment.

Patients with renal impairment, except for those on dialysis, do not require starting dose adjustments.

View POMALYST Renal Dosing


Dose modifications may help patients with relapsed/refractory multiple myeloma stay on treatment.

View More Dose Modifications

CBC, complete blood count; dex, dexamethasone.

Reference: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp.

POMALYST can be used in patients with severe
renal impairment, including those on dialysis.1

See Renal Dosing